BD nabs $25M in energy savings; Endo settles more vaginal mesh suits;

@FierceMedDev: ICYMI: Magic material: graphene protects chemotherapy, but silver-lined catheters break it down. Article | Follow @FierceMedDev

@StacyALawrence: Aum Cardio raises $5M to back hand-held, in-office CAD Dx device. Article | Follow @StacyALawrence

@EmilyWFierce: The experience of having your blood drawn by Theranos, as laid out by @danmunro. More | Follow @EmilyWFierce

> Becton Dickinson ($BDX) has saved more than $25 million in its efforts to become more energy efficient over the last 5 years. It's laid out its sustainability goals through 2020 in a new report. More

> Endo's ($ENDP) American Medical Systems has settled more than 100 lawsuits related to its vaginal mesh devices Apogee and Perigee. More

> Mitek Sports Medicine, part of Johnson & Johnson ($JNJ) company DePuy Synthes, is launching two new hand-held, energy-based radiofrequency orthopedic devices: the VAPR TRIPOLAR 90 Suction Electrode and the VAPR ARCTIC Suction Electrode. More

> Grove Instruments, which had hoped to develop a device to measure blood sugar without needles, has filed for bankruptcy instead. Here's the story of its downfall. Article

Biotech News

@FierceBiotech: Roche hustles to FDA with PhII PD-L1 cancer success for 'breakthrough' star atezolizumab. News | Follow @FierceBiotech

@JohnCFierce: You want to see why execs are leaving Big Pharma for biotech? It's where the money is. Report | Follow @JohnCFierce

@DamianFierce: Actual line: "Sorrento recently entered into a definitive agreement with NantPharma to acquire the rights for Cynviloq™ from Sorrento." | Follow @DamianFierce

> As schizophrenia rivals rush in, Otsuka and Lundbeck gain FDA OK for Rexulti. News

> Anacor soars as its eczema cream succeeds in Phase III. Article

Pharma News

@FiercePharma: Did squirrels pass a killer virus to people? FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Which companies had highest comped CEOs? Hint, most are U.S. and did not necessarily make the most money. Special report | Follow @EricPFierce

@CarlyHFierce: I triple-dog-dare someone to make this new creepy-as-hell $GSK vaccine ad their Twitter pic. Photo | Follow @CarlyHFierce

> Otsuka, Lundbeck bag blockbuster FDA approval for long-acting antipsychotic Rexulti. More

> European safety watchdog digs into HPV vaccines again. Article

Animal Health News

> FDA cracks down on Vegas firm selling unapproved kidney drug for dogs and cats. Article

> Perdue ditches all antibiotics for new chicken line, General Mills goes cage-free. Report

> Did squirrels pass a killer virus to people? More

> Senate committee, USDA, poultry producers meet to discuss deadly U.S. avian flu outbreak. Story

> Sweden's Oasmia regains rights to cancer drugs from Zoetis, files for $23M IPO. Article

Biotech IT News

> 21st Century Cures Act clears House with data sharing, standardization sections intact. Story

> Genomics vs YouTube: Which will have the greater computing requirements in 2025? More

> GSK working to build Apple's ResearchKit into its clinical trials. Report

> Financially motivated hackers break into 3 major pharma companies in 18 months. Article

> Core Informatics snags $17.5M to fuel lab software land grab. Story

Pharma Marketing News

> Novartis off to scorching start with Copaxone generic Glatopa. Article

> Novo Nordisk looks past blockbuster Victoza with PhIII success for weekly GLP-1 med. Item

> For Entresto rollout, Novartis marketing mixes tried-and-true with new-and-different. Story

> How does the Keytruda-Opdivo marketing battle stack up? More

> GSK's big, bad whooping cough vaccination campaign bares its teeth. Article

Suggested Articles

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years.